In the last 12 months, insiders at Addex Therapeutics neither bought nor sold shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Timothy Mark Dyer | Chief Executive Officer | 16,848,979 | 0 | 16,848,979 | 75.7% | 04 Sep, 2026 |
| 2 | Vincent Michael Lawton | Director | 2,507,987 | 0 | 2,507,987 | 11.3% | 04 Sep, 2026 |
| 3 | Raymond George Hill | Director | 1,365,532 | 0 | 1,365,532 | 6.1% | 04 Sep, 2026 |
| 4 | Roger Mills | Chief Medical Officer | 785,976 | 0 | 785,976 | 3.5% | 04 Sep, 2026 |
| 5 | Mikhail Kalinichev | Head Of Translational Science | 306,765 | 0 | 306,765 | 1.4% | 04 Sep, 2026 |
| 6 | Jason Raleigh Nunn | Director | 219,561 | 0 | 219,561 | 1.0% | 04 Sep, 2026 |
| 7 | Isaac Manke | Director | 219,561 | 0 | 219,561 | 1.0% | 04 Sep, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 02 Sep, 2026 | Mikhail Kalinichev | Head Of Translational Science | Disposed D | 306,765 | $0.00 | $0 | 0 | Direct |
| 02 Sep, 2026 | Vincent Michael Lawton | Director | Disposed D | 2,507,487 | $0.00 | $0 | 500 | Direct |
| 02 Sep, 2026 | Jason Raleigh Nunn | Director | Disposed D | 219,561 | $0.00 | $0 | 0 | Direct |
| 02 Sep, 2026 | Roger Mills | Chief Medical Officer | Disposed D | 392,837 | $0.00 | $0 | 393,139 | Direct |
| 02 Sep, 2026 | Isaac Manke | Director | Disposed D | 219,561 | $0.00 | $0 | 0 | Direct |
| 02 Sep, 2026 | Raymond George Hill | Director | Disposed D | 1,365,532 | $0.00 | $0 | 0 | Direct |
| 02 Sep, 2026 | Lenaic Nathanael Teyssedou | Principal Accounting Officer | Disposed D | 37,770 | $0.00 | $0 | 565,138 | Direct |
| 02 Sep, 2026 | Timothy Mark Dyer | Chief Executive Officer | Disposed D | 16,413,787 | $0.00 | $0 | 435,192 | Direct |
| 02 Sep, 2026 | Raymond George Hill | Director | Acquired A | 1,365,532 | $0.00 | $0 | 1,365,532 | Direct |
| 02 Sep, 2026 | Lenaic Nathanael Teyssedou | Principal Accounting Officer | Acquired A | 37,770 | $0.00 | $0 | 602,908 | Direct |
| 02 Sep, 2026 | Vincent Michael Lawton | Director | Acquired A | 2,507,487 | $0.00 | $0 | 2,507,987 | Direct |
| 02 Sep, 2026 | Mikhail Kalinichev | Head Of Translational Science | Acquired A | 306,765 | $0.00 | $0 | 306,765 | Direct |
| 02 Sep, 2026 | Timothy Mark Dyer | Chief Executive Officer | Acquired A | 16,413,787 | $0.00 | $0 | 16,848,979 | Direct |
| 02 Sep, 2026 | Jason Raleigh Nunn | Director | Acquired A | 219,561 | $0.00 | $0 | 219,561 | Direct |
| 02 Sep, 2026 | Roger Mills | Chief Medical Officer | Acquired A | 392,837 | $0.00 | $0 | 785,976 | Direct |
| 02 Sep, 2026 | Isaac Manke | Director | Acquired A | 219,561 | $0.00 | $0 | 219,561 | Direct |
| 02 Sep, 2026 | Lenaic Nathanael Teyssedou | Principal Accounting Officer | Disposed D | 59,530 | $0.00 | $0 | 543,378 | Direct |
| 02 Sep, 2026 | Mikhail Kalinichev | Head Of Translational Science | Disposed D | 200,000 | $0.00 | $0 | 0 | Direct |
| 02 Sep, 2026 | Jason Raleigh Nunn | Director | Disposed D | 50,000 | $0.00 | $0 | 0 | Direct |
| 02 Sep, 2026 | Raymond George Hill | Director | Disposed D | 273,107 | $0.00 | $0 | 0 | Direct |